Location: Home
  • search
  • go
  • Relate News
  • 4/11/2024Drugmakers Race to Find Alternative Suppliers as US Cracks Down on Chi...
  • 4/8/2024Boehringer Ingelheim and Sino Biopharm Enter Strategic Deal to Develop...
  • 4/2/2024Aurisco Launches State-of-the-Art Manufacturing Facility for GLP-1 Pep...
  • 3/29/2024WuXi AppTec Shared US Client's Data with Beijing (Reuters)
  • 3/29/2024Small Biotechs Reveal Reliance on Chinese CDMOs (BioCentury)
  • 3/27/2024U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies (WSJ...
  • 3/27/2024BIOSECURE Act May Implicate WuXi-Produced Drugs in the US Market
  • 3/26/2024Anti-China Bills Portend Massive Blow to Biotech: BioCentury Survey (B...
  • 3/20/2024China Ranked Top Potential Biopharma Outsourcing Destination (Bioproce...
  • 3/20/2024WuXi Biologics Breaks Ground on State-of-the-Art $1.4 Billion CRDMO Fa...
  • 3/20/2024WuXi XDC Builds Singapore Manufacturing Facility for Global Bioconjuga...
  • 3/18/2024The US and Chinese Biopharma Contractors (Science)
  • 2/16/2024Anti-China Biotech Policy: Biosecure & Beyond (BioCentury Video)
  • 2/5/2024U.S. Congress Postpones Legislation Targeting Chinese Biotech Firms
  • 1/29/2024Lonza to Close Biologics Plant in Guangzhou after Only Three Years of ...
  • 1/29/2024Proposed US Legislation Rattles Chinese Biopharma Cos amid National Se...
  • 1/25/2024Celltrion, China's WuXi Bolster Ties on ADC Partnership
  • 1/23/2024Jiuzhou Pharma to Build $42M Drug R&D Platform in Japan for Foreign Cl...
  • 1/11/2024WuXi Biologics Announces Research Service Agreement with BioNTech on N...
  • 1/10/2024WuXi Biologics Expands Manufacturing Capacity in the US
  • 1/6/2024Boehringer Ingelheim partners with Ribo to develop new treatments for ...
  • 12/25/2023Oncoshot Teams Up with Zhejiang Ablaze Medicine to Drive Data-Powered ...
  • 12/10/2023WuXi Biologics Successfully Implemented a Fully Integrated Continuous ...
  • 11/13/2023Boehringer Ingelheim and ChromX Health Join Hands to Research Lung Dis...
  • 11/7/2023WuXi XDC Eyes Up to $471M in Hong Kong IPO
  • 11/1/2023Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
  • 10/17/2023China: The New Frontier for Western CDMOs? (Contract Pharma)
  • 9/28/2023Chime Biologics Enters Strategic Deal with Kings Pharm to Accelerate B...
  • 9/26/2023China's Shifting Cost Dynamic to Help It Develop Own Biologics Niche: ...
  • 9/26/2023WuXi Debuts First Vaccine CDMO Site in China
  • Page:1/18 Total number of articles:513: [First][<<] [1] [2] [3] [4] [5] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group